Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
https://www.zacks.com/stock/news/2193809/roche-rhhby-breast-cancer-drug-meets-primary-goal-in-phase-iii?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193809
Dec 05, 2023 - Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.
0
Pages: 12
<Page 2